TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05276726: A Phase Ib/II ,Single Arm, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of JAB-21822 in Advanced or Metastatic Non-small Cell Lung Cancer With a KRAS p.G

Sponsor: Allist Pharmaceuticals, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 104 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,600,130

Rescue Site Savings

+$5,694,150

Unlock Full NCT05276726 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05276726 Rescue Dossier →